Popular on TelAve
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- The ITeam Ranked on Channel Partners 2025 MSP 501—Tech Industry's Most Prestigious List of Managed Service Providers Worldwide
- Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- TCAA Welcomes Adolfo Gomez Sanchez to Its Family of Talented Speakers
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
Similar on TelAve
- Pixel Studio Productions Launches Same-Day Headshots in Houston
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
SFA Therapeutics Announces FDA Approval To Begin IND Trial
TelAve News/10632291
Clinical Trial Examines Human Micro-biome-based Drug SFA002 In Mild to Moderate Plaque Psoriasis
PHILADELPHIA - TelAve -- SFA Therapeutics, Inc. is pleased to announce that the US FDA has provided approval to conduct a clinical trial (officially referred to as an IND) for the treatment of "the appearance of the structure of skin with plaques due to psoriasis." SFA plans to expand the evaluation of one of its five microbiome-derived drugs, SFA002, in this new trial.
This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation. Treatment duration will be three months, after which patients will be observed for an additional three months.
The Need for an Oral Treatment of Mild to Moderate Psoriasis Remains Acute
More on TelAve News
"Significant clearing of psoriatic plaques has already been demonstrated with SFA002 in a small study," commented SFA CEO Dr. Ira Spector, "and, because we know that this patient group has lacked an effective and safe oral treatment option, we are going into this larger IND trial with considerable optimism."
Study recruitment is planned to begin in the Fall of 2020. Following the trial's completion, SFA expects to finalize the SFA002 formulation and proceed into a randomized controlled clinical trial.
Please contact SFA Therapeutics COO, James Kirwin, at jameskirwin@sfatherapeutics.com for additional information.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting Psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
More on TelAve News
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit sfatherapeutics.com to learn more.
This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation. Treatment duration will be three months, after which patients will be observed for an additional three months.
The Need for an Oral Treatment of Mild to Moderate Psoriasis Remains Acute
More on TelAve News
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
"Significant clearing of psoriatic plaques has already been demonstrated with SFA002 in a small study," commented SFA CEO Dr. Ira Spector, "and, because we know that this patient group has lacked an effective and safe oral treatment option, we are going into this larger IND trial with considerable optimism."
Study recruitment is planned to begin in the Fall of 2020. Following the trial's completion, SFA expects to finalize the SFA002 formulation and proceed into a randomized controlled clinical trial.
Please contact SFA Therapeutics COO, James Kirwin, at jameskirwin@sfatherapeutics.com for additional information.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting Psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
More on TelAve News
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- Nonprofit innovator named Mensa Executive Director
- Yasmine Roulleau named Managing Director in Vancouver, Canada
- Chasing Elizabeth Taylor — The Dazzling True Story Behind the Queen of Diamonds Now Available in Limited-Edition Hardcover
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit sfatherapeutics.com to learn more.
Source: SFA Therapeutics, Inc.
0 Comments
Latest on TelAve News
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Cellhire boosts its EE offering via deal with BT Wholesale's Complete Mobile
- 24/7 customizable AI answering service from Kell Web Solutions, Inc. helps businesses never miss a customer call, lead, or appointment again
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Next-generation virtual receptionist service leverages AI to ensure every customer call and text is answered, enhancing efficiency and engagem
- New AI-Powered Platform from Kell Web Solutions Delivers 24/7 Professional, Automated Call Handling and Appointment Scheduling
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety